Two previous studies revealed no mortality benefit of antiplatelet therapy (including aspirin and P2Y12 inhibitors) as an add-on therapy among hospitalized noncritically ill COVID‐19 patients [17,18]. This evidence concerns the gene P2RY12 and COVID-19.